In addition to treating hyperuricemia, previous studies have found that xanthine oxidase can regulate the activation of the NLRP3 inflammasome, thereby targeted-treating NAFLD (Xu et al., 2015). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.